Skip to main content
Clinical Trials/CTRI/2025/02/080756
CTRI/2025/02/080756Not yet recruitingNot Applicable

Movement Imitation Therapy v/s Standard Care in Very Preterm and Extreme Preterm Neonates: A Randomised Controlled Trial (MOTIVE trial)

Sri Ramachandre Institute of Higher Education and Research1 site in 1 country60 target enrollmentStarted: March 3, 2025Last updated:

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
Enrollment
60
Locations
1
Primary Endpoint
General Movement Optimality Score- Revised (GMOS-R) at 34 weeks Post Menstrual Age (PMA)

Study Overview

Brief Summary

The MOTIVE trial is a randomized controlled study comparing Movement Imitation Therapy (MIT) to standard care in very preterm and extreme preterm neonates. Conducted at Sri Ramachandra Institute of Higher Education and Research, the study aims to assess the impact of MIT on neurodevelopmental outcomes using the General Movement Optimality Score-Revised (GMOS-R) at 34 weeks post-menstrual age (PMA). The trial will involve stratified randomization of eligible preterm neonates, with MIT sessions incorporating guided limb movements mimicking normal general body movements. Secondary outcomes include GMOS-R at 5 months of corrected age, MRI/Neurosonogram findings at term-equivalent age, and the Hammersmith Neonatal Neurological Examination (HNNE) scores. The study follows ethical guidelines, ensuring informed parental consent and confidentiality, with blinded outcome assessment to minimize bias.

Study Design

Study Type
Interventional
Allocation
Randomized
Masking
Outcome Assessor Blinded

Eligibility Criteria

Ages
7.00 Day(s) to 14.00 Day(s) (—)
Sex
All

Inclusion Criteria

  • All pre-term neonates born between 26wks 0/7 to 31wks 6/7 weeks gestational age, admitted in Neonatal Intensive Care unit, and who are hemodynamically stable, from their second week of life.

Exclusion Criteria

  • Neonates with genetic or congenital anomalies affecting motor function.

Outcomes

Primary Outcomes

General Movement Optimality Score- Revised (GMOS-R) at 34 weeks Post Menstrual Age (PMA)

Time Frame: At 34 weeks Post Menstrual Age (PMA)

Secondary Outcomes

  • 1. GMOS-R at 5 months of chronological age(2. Neurosonogram/MRI brain at term equivalent age)

Investigators

Sponsor
Sri Ramachandre Institute of Higher Education and Research
Sponsor Class
Research institution and hospital
Responsible Party
Principal Investigator
Principal Investigator

Dr Meghana S

Sri Ramachandra Institute of Higher Education and Research

Study Sites (1)

Loading locations...

Similar Trials

Movement Imitation Therapy to see its... | Clinical Trial